Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Get Free Report) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 451,633 shares, an increase of 5,382.3% from the August 31st total of 8,238 shares. Currently, 163.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,671,517 shares, the short-interest ratio is presently 0.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.
View Our Latest Stock Report on SCNI
Scinai Immunotherapeutics Trading Down 6.1%
Shares of Scinai Immunotherapeutics stock traded down $0.12 during trading on Thursday, hitting $1.86. The stock had a trading volume of 149,722 shares, compared to its average volume of 504,096. The firm’s fifty day simple moving average is $2.34 and its 200-day simple moving average is $4.04. The stock has a market cap of $1.32 million, a PE ratio of -0.02 and a beta of 2.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.35. Scinai Immunotherapeutics has a 12 month low of $1.43 and a 12 month high of $16.30.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure.
Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets.
See Also
- Five stocks we like better than Scinai Immunotherapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
